TY - JOUR AU - Guerrero, Whitney AU - Munene, Gitonga AU - Dickson, Paxton V. AU - Stiles, Zachary E. AU - Mays, Johnathan AU - Davidoff, Andrew M. AU - Glazer, Evan S. AU - Shibata, David AU - Deneve, Jeremiah L. PY - 2018 TI - Outcome and factors associated with aborted cytoreduction for peritoneal carcinomatosis JF - Journal of Gastrointestinal Oncology; Vol 9, No 4 (August 01, 2018): Journal of Gastrointestinal Oncology Y2 - 2018 KW - N2 - Background: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) offers a potential cure for peritoneal carcinomatosis (PC), whereas aborted cytoreduction is associated with a poor outcome. We evaluate factors associated with aborted CRS procedures. Methods: An IRB approved retrospective review was performed from 12/2011 to 2/2016. Clinicopathologic variables and outcomes are described. Results: Seventy-four patients underwent attempted CRS/HIPEC which was completed in 51 (69%) and aborted in 23 (31%). There was no difference in age, race, gender or prior treatment between groups. Patients who underwent aborted procedures had a higher peritoneal cancer index (PCI, 26.1±9.9 vs . 16.2±10.5, P=0.001). Overall survival (OS) was significantly improved for patients who underwent completed CRS/HIPEC (41.0±10.4 vs. 6.0±2.3 months, P<0.0001). Patients with an appendiceal and colorectal primary who underwent CRS/HIPEC had a significantly better outcome (median not reached vs. 6±5.4 months, P<0.0001, and 28.0±7.5 vs. 8.0±4.0 months, P<0.0001, respectively). Colorectal pathology (P=0.014) and PCI score (<0.0001) were independent predictors of aborted CRS procedures. Conclusions: One-third of patients with PC had significant disease which prevented successful completion of CRS/HIPEC. PCI and colorectal primary tumor pathology were associated with a greater likelihood of aborted CRS procedures. UR - https://jgo.amegroups.org/article/view/21477